Core Viewpoint - The stock of Shangrong Medical (002551) has shown a recent increase in price, but the company's financial performance indicates significant challenges, including declining revenues and profits [1][2]. Group 1: Stock Performance - As of January 5, 2026, Shangrong Medical's stock closed at 3.79 yuan, up 3.84%, with a turnover rate of 2.79% and a trading volume of 170,500 hands, amounting to a total transaction value of 63.98 million yuan [1]. - On January 5, 2026, the net inflow of main funds was 9.75 million yuan, accounting for 15.23% of the total transaction value, while retail investors experienced a net outflow of 6.31 million yuan, representing 9.85% of the total [1]. Group 2: Financial Indicators - Shangrong Medical's total market capitalization is 3.204 billion yuan, significantly lower than the industry average of 11.28 billion yuan, ranking 101 out of 125 in the industry [2]. - The company reported a net profit of -35.13 million yuan for the first three quarters of 2025, a decline of 338.5% year-on-year, with a gross margin of 14.35%, which is substantially below the industry average of 51.02% [2]. - The company's return on equity (ROE) stands at -1.34%, ranking 108 out of 125 in the industry, indicating poor profitability compared to peers [2].

Core Viewpoint - The company, Shangrong Medical, has experienced a slight decline in stock price and has held a significant shareholder meeting to approve various governance changes and the reappointment of its accounting firm [1][2][3] Group 1: Stock Performance - As of December 31, 2025, Shangrong Medical's stock closed at 3.65 yuan, down 1.35% from the previous week [1] - The stock reached a high of 3.71 yuan and a low of 3.6 yuan during the week [1] - The company's current total market capitalization is 3.086 billion yuan, ranking 104th out of 127 in the medical device sector and 4480th out of 5181 in the A-share market [1] Group 2: Shareholder Meeting Announcements - The company held its second extraordinary general meeting on December 29, 2025, where it combined on-site and online voting to approve the reappointment of the accounting firm, amendments to the company’s articles of association, and changes to governance systems [2][3] - The amendments to the articles of association and certain governance systems were special resolutions that received over two-thirds of the voting rights from attending shareholders [2] - The meeting's resolutions were deemed legally valid, supported by a legal opinion from Guangdong Huashang Law Firm [2] Group 3: Board Changes - Non-independent director and deputy general manager Zhang Jierui resigned due to internal work adjustments but will continue to hold other positions within the company [1][3] - On the same day, Zhang Jierui was elected as a representative director of the eighth board, with a term lasting until the current board's term ends [1][3] - The board remains compliant with the required number of directors, maintaining a total of nine members [1]

Group 1 - The stock of Shangrong Medical (002551) closed at 3.68 yuan on December 29, 2025, down 0.54% from the previous trading day, with a total market capitalization of 3.111 billion yuan [1] - The stock opened at 3.7 yuan, reached a high of 3.71 yuan, and a low of 3.65 yuan, with a trading volume of 29.3504 million yuan and a turnover rate of 1.31% [1] - The Guangdong Huashang Law Firm issued a legal opinion regarding the second extraordinary general meeting of shareholders for Shangrong Medical in 2025, confirming that the meeting's procedures and resolutions complied with relevant laws and company regulations [1] Group 2 - The shareholders' meeting approved several resolutions, including the reappointment of the accounting firm, amendments to the company’s articles of association, revisions to multiple corporate governance systems, and the decision to no longer exercise the powers of the supervisory board [1]

Core Viewpoint - Shangrong Medical announced the convening of its second extraordinary general meeting of shareholders for 2025 on December 29, 2025, to review multiple proposals, including the reappointment of the accounting firm [2] Group 1 - The company will hold the extraordinary general meeting on December 29, 2025 [2] - The agenda includes the proposal for the reappointment of the accounting firm [2]

Core Viewpoint - The company announced the resignation of non-independent director and vice president Zhang Jierui due to internal work adjustments, but he will continue to hold other positions within the company [1] Group 1 - Zhang Jierui submitted a written resignation report to the company's board of directors [1] - His resignation will not reduce the number of board members below the legal minimum and will not affect the normal operation of the board [1] - The resignation report becomes effective upon delivery to the company's board of directors [1]

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-058 深圳市尚荣医疗股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关于非独立董事辞职的情况 深圳市尚荣医疗股份有限公司（以下简称"公司"）董事会于近日收到公司非独 立董事、副总经理张杰锐先生递交的书面辞职报告。因公司内部工作调整，张杰锐先 生申请辞去公司第八届董事会非独立董事、副总经理职务。辞职后将继续在公司担任 其他职务。张杰锐先生担任公司第八届董事会非独立董事的原定任期为 2024 年 10 月 21 日至 2027 年 10 月 20 日。截止本公告披露日，张杰锐先生不存在应当履行而未履 行的承诺事项，根据《中华人民共和国公司法》（以下简称"《公司法》"）及《深 圳市尚荣医疗股份有限公司章程》（以下简称"《公司章程》"）等相关规定，张杰 锐先生的辞职不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正 常运作，其辞职报告自送达公司董事会起生效。 张杰锐先生当选公司职工代表董事后，公司第八届董事会成员数量仍为 9 名， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年第二次临时股东大会（以下简称"本次股东大会"）召开期间未出 现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采取现场投票和网络投票相结合的方式召开。 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-059 深圳市尚荣医疗股份有限公司 2025 年第二次临时股东大会决议公告 一、会议召开及出席情况 （一）会议召开情况 1、会议召集人：公司董事会。 2、会议时间： （1）现场会议召开时间：2025年12月29日（星期一）下午14:30； （2）网络投票时间：2025年12月29日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年12月29 日的交易时间即：9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易 所互联网投票系统投票的时间为2025年12月29日上午9:15至下午15:00 期间任意 时间。 3、现场会议召开地点：深圳市龙岗区宝龙工业城宝龙5路2号尚荣科技工业 园公司会议室。 ...

法律意见书 广东华商律师事务所 关于深圳市尚荣医疗股份有限公司 2025年第二次临时股东大会的 法律意见书 二○二五年十二月二十九日 1 法律意见书 致：深圳市尚荣医疗股份有限公司 广东华商律师事务所（以下简称"本所"）接受深圳市尚荣医疗股份有限公 司（以下简称"公司"）的委托，指派本所周玉梅律师、邓娇律师（以下简称"本 所律师"）出席公司2025年第二次临时股东大会（以下简称"本次会议"）。本 所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法 律、法规和规范性法律文件以及《深圳市尚荣医疗股份有限公司章程》（以下简 称"《公司章程》"）的规定，出具本法律意见书。 经本所律师核查，公司本次会议于2025年12月29日下午14：30在深圳市龙岗 区宝龙工业城宝龙5路2号尚荣科技工业园尚荣医疗会议室召开，会议由公司董事 2 法律意见书 长梁桂秋先生主持，会议召开的时间、地点、审议事项与《股东大会通知》所告 知的内容一致。本次会议采取现场投票与网络投票相结合的方式，公司通过深圳 证券交易所交易系统和互联网投票系统（http: ...

Core Viewpoint - Shangrong Medical (002551) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a total revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The net profit after deducting non-recurring items was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company recorded a quarterly revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The quarterly net profit attributable to shareholders was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin is reported at 14.35% [2]. Stock Performance - As of December 26, 2025, Shangrong Medical's stock closed at 3.7 yuan, down 1.07% with a turnover rate of 1.34% [1]. - The trading volume was 81,900 hands, with a total transaction value of 30.45 million yuan [1]. - On December 26, the net inflow of main funds was 2.63 million yuan, accounting for 8.64% of the total transaction value, while retail investors saw a net outflow of 1.74 million yuan, representing 5.7% of the total transaction value [1].

Group 1 - The core point of the article highlights that Shangrong Medical (002551) experienced a stock price increase of 1.63% to 3.74 yuan as of December 25, 2025, with a trading volume of 73,200 hands and a total transaction amount of 27.16 million yuan [1] - On December 25, the net inflow of main funds was 2.38 million yuan, accounting for 8.78% of the total transaction amount, while retail investors saw a net outflow of 2.18 million yuan, representing 8.01% of the total transaction amount [1][2] - The company's Q3 2025 report indicates a significant decline in revenue, with a total revenue of 755.4 million yuan, down 24.85% year-on-year, and a net profit attributable to shareholders of -35.13 million yuan, a decrease of 338.5% [2] Group 2 - In Q3 2025, the company's single-quarter revenue was 225 million yuan, reflecting a year-on-year decrease of 39.25%, and the net profit attributable to shareholders was -27.37 million yuan, down 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan, while the gross profit margin is reported at 14.35% [2]